BMT Tandem Meetings 2014


The Gaylord Texan Resort & Convention Center, site of the 2014 BMT Tandem Meetings.

The 2014 BMT Tandem Meetings took place February 26 to March 2 in Grapevine, Texas.


Analysis details effects of HLA mismatch

Jen Smith Read Article
Published: 03/14/14

Joseph Pidala, MD
Credit: Steven Hacker
BMT Tandem Meetings

An analysis of more than 8000 patients provides insights regarding HLA disparity that may help optimize outcomes in individuals undergoing unrelated-donor hematopoietic stem cell transplant. The study showed that a single allele- or antigen-level HLA mismatch (7/8) increased the risk for acute and chronic graft-vs-host disease (GVHD) and worsened survival rates. However, there were no locus-specific effects on survival, and there was no impact of allele- vs antigen-level mismatch on survival.  [Read Article]

T cells protect from GVHD, preserve GVT effect

Jen Smith Read Article
Published: 03/12/14

Dominik Schneidawind, MD
Credit: Steven Hacker
BMT Tandem Meetings

Adding specialized T cells to allogeneic bone marrow transplants can prevent graft-vs-host disease (GVHD) while preserving the graft-vs-tumor (GVT) effect, preclinical research suggests. Donor-derived CD4+ invariant natural killer T cells (iNKT cells) helped protect mice from developing GVHD and lymphoma, thereby improving their survival. As human CD4+ iNKT cells can be expanded in vitro, these findings may translate to the clinic, said Dominik Schneidawind, MD, of Stanford University. [Read Article]

Order of Cy, TBI doesn’t impact HSCT outcome

Jen Smith Read Article
Published: 03/11/14

Cyclophosphamide drip
Credit: Linda Bartlett

The order in which patients receive cyclophosphamide (Cy) and total body irradiation (TBI) does not affect the outcome of hematopoietic stem cell transplant (HSCT), researchers have reported. In a large, retrospective study, the rates of relapse, survival, chronic graft-vs-host disease (GVHD), and other complications were similar whether patients received Cy-TBI or TBI-Cy. However, receiving Cy-TBI was associated with a slight decrease in the risk of grade 2-4 acute GVHD.  [Read Article]

RIT can improve transplant outcomes in NHL, CLL

Jen Smith Read Article
Published: 03/07/14

Ryan Cassaday, MD
Credit: Steven Hacker
BMT Tandem Meetings

Administering radioimmunotherapy (RIT) prior to non-myeloablative allogeneic transplant (NMAT) can improve survival in patients with persistent disease, according to a speaker at the 2014 BMT Tandem Meetings. Ryan Cassaday, MD, of the University of Washington in Seattle, noted that RIT-augmented NMAT can produce long-term remissions in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) or chronic lymphocytic leukemia (CLL).  [Read Article]

Study links graft source to length of hospital stay

Jen Smith Read Article
Published: 03/06/14

Cord blood donation
Credit: NHS

Acute leukemia patients who undergo cord blood (CB) transplant have longer hospital stays than patients who receive other types of transplant, new research indicates. The study also suggests the length of stay (LOS) is similar whether patients receive double or single CB grafts. So it seems strategies are needed to decrease hospital stay after CB transplant, particularly as LOS drives the cost of care, said Karen K. Ballen, MD, of Massachusetts General Hospital in Boston. [Read Article]

CNS involvement doesn’t affect survival after allo-SCT

Jen Smith Read Article
Published: 03/05/14

Preparation for SCT
Credit: Chad McNeeley

Results of a large, retrospective study suggest that allogeneic stem cell transplant (allo-SCT) can overcome the poor prognosis associated with central nervous system (CNS) involvement in acute myeloid leukemia (AML). By analyzing transplant outcomes in more than 5000 patients, researchers found that subjects with CNS AML had rates of relapse and survival that were similar to those of patients without CNS involvement. The team also identified factors . . . [Read Article]

Bacteria may protect against GVHD-related mortality

Jen Smith Read Article
Published: 03/04/14

Robert Jenq, MD
Credit: Steven Hacker
BMT Tandem Meetings

Intestinal bacteria can offer protection from death related to graft-vs-host disease (GVHD), according to research presented at the 2014 BMT Tandem Meetings. Experiments showed that Blautia, commensal bacteria found in the intestinal tract, can protect against GVHD-related mortality in mice and in humans. So efforts to support Blautia survival—such as restricting the use of antibiotics and promoting better nutrition—may prevent GVHD-related death. [Read Article]

TNC dose can affect PFS, OS after PBSCT

Jen Smith Read Article
Published: 03/03/14

Apheresis machine

The total nucleated cell (TNC) dose delivered in an allogeneic peripheral blood stem cell transplant (allo-PBSCT) can affect outcomes in certain patients, according to a study presented at the 2014 BMT Tandem Meetings. Researchers found that a higher TNC dose was associated with better progression-free survival (PFS) and overall survival (OS) among patients who received allo-PBSCT with reduced-intensity conditioning (RIC) and total-body irradiation (TBI). [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}